PIK3CG and neoplasm: Additionally, IPI‐549, which targets tumor‐associated myeloid cells through selective inhibition of PI3K‐gamma, demonstrated promising efficacy when administered as a triplet therapy with both atezolizumab and chemotherapy in first‐line.41